The U.S. Food and Drug Administration issued a Complete Response Letter to Merck & Co. for the company’s New Drug Application for gefapixant for refractory chronic cough or unexplained chronic cough.
AI Can Detect Covid-19 by Analyzing Coughs and More Related Research
ACE2 (angiotensin-converting enzyme-2), Antibodies, Artificial Intelligence, Blood Samples, Brigham and Women's Hospital, Cells, Children, Coronavirus Disease 2019 (COVID-19), Cough, Massachusetts Institute of Technology (MIT), Mouth, R&D, Researchers, RNA, Science Translational MedicineResearchers at Massachusetts Institute of Technology (MIT) developed an artificial intelligence (AI) model able to detect asymptomatic Covid-19 cases by identifying differences in the sounds of coughs between healthy and infected people.
The wind howls and new-fallen leaves swirl around. There’s a sense of dread hanging in the air. Monsters are about, spreading terror across the land. The sound of coughing and gasping breath is coming up fast. A slow look over your shoulder reveals the sweaty, nightmare visage of Covid-19 – or does it?
The U.S. Centers for Disease Control and Prevention warned that Covid-19 could spread through airborne particles that can remain suspended in the air and travel beyond six feet.
Vernalis plc announces today that the US Food and Drug Administration issued a Complete Response Letter (CRL) regarding the New Drug Application for CCP-07.
Merck & Co. is acquiring Afferent Pharmaceuticals for an upfront cash payout of $500 million of stock and an additional $750 million based on various clinical and commercial milestones.